South Korea Launches Whole-Genome Sequencing Initiative for Newborn Rare Disease Screening

Per the Asia Business Daily, the National Institute of Health under the Korea Disease Control and Prevention Agency has begun participant recruitment for a whole-genome sequencing newborn screening protocol designed to detect treatable rare genetic diseases before clinical onset — a substantial expansion of the Korean newborn screening panel, which currently covers only congenital metabolic disorders and hearing loss. The agency formally launched enrollment on September 7 for its "Genome-wide Sequencing-Based Newborn Screening Study," targeting a cohort of 1,800 newborns across a three-year window.

Assay design and enrollment parameters

The protocol specifies whole-genome analysis of healthy newborns within 28 days of birth, sequenced to detect pathogenic variants associated with treatable congenital conditions. Phased parameters:

• Year-one enrollment cap: 500 participants
• Total target enrollment: 1,800 by 2028
• Pre-launch groundwork completed in April: multidisciplinary consortium formation, Institutional Review Board approval, recruitment and counseling infrastructure
• Participant enrollment commenced approximately one month before the formal September 7 announcement

The phased enrollment structure permits interim analysis at the year-one mark and provides a defined timeline against which protocol adjustments can be evaluated.

Panel scope: targeted assays versus genome-wide sequencing

Korean newborn screening currently restricts coverage to a narrow condition set: congenital metabolic disorders and hearing loss. The genome-wide protocol extends detection capacity to a substantially broader range of rare genetic diseases by interrogating the full genomic sequence rather than a defined biochemical or auditory analyte panel.

The prior-year pilot project supplied the methodological foundation, establishing:

• Target disease and gene lists for the screening panel
• Patient consent procedures appropriate for genomic data
• Clinical guidelines for result interpretation and follow-up

The current validation study extends that pilot infrastructure into a formal clinical evidence base, leveraging pre-built operational components rather than initiating protocol development from scratch.

Validation endpoints and policy pathway

The validation cohort will measure three primary endpoints: diagnostic efficiency, clinical benefit, and economic utility of genome-based screening relative to existing biochemical and auditory assays. Output metrics are intended to populate an evidence base sufficient to support national policy implementation — specifically, the establishment of a Korean-style genome-wide newborn screening framework as a public health program. KDCA Commissioner Im Seungkwan, quoted by the Asia Business Daily, stated: "The earlier a rare genetic disease is detected, the more significant the effects of treatment and the prognosis, making it especially important to establish an accurate diagnostic system during the newborn period."